がん治療におけるフェロプトーシス:課題、機会、および将来の方向性
Rui Kang1, Jiao Liu2, Jiayi Wang3,4
1Department of Surgery, UT Southwestern Medical Center, Dallas, TX, USA. rui.kang@utsouthwestern.edu.
Nature reviews. Clinical oncology
|February 24, 2026
まとめ
細胞死経路であるフェロプトーシスは、がん治療において有望であるが、臨床応用にはハードルがある。本レビューでは、フェロプトーシスに基づくがん治療の課題と機会を探る。
科学分野:
- 腫瘍学
- 細胞生物学
- 生化学
背景:
- フェロプトーシスは、脂質過酸化によって駆動される、制御された細胞死経路である。
- がんにおいて、腫瘍抑制的および腫瘍促進的な両方の複雑な役割を果たす。
- フェロプトーシスの治療標的化は、がん研究において大きな関心事である。
研究 の 目的:
- フェロプトーシスに基づくがん治療の臨床応用を妨げる障壁をレビューすること。
- フェロプトーシス治療を進歩させるための新たな機会と戦略を特定すること。
- 臨床腫瘍学の実践にフェロプトーシスを統合するためのロードマップを提案すること。
主な方法:
- がんにおけるフェロプトーシスに関する包括的な文献レビュー。
- フェロプトーシス誘導剤に関する前臨床および臨床データの分析。
- 薬理学的、生物学的、および免疫学的な要因を含む課題の検討。
主要な成果:
- フェロプトーシス研究における著しい前臨床的進歩は、初期段階にある臨床応用とは対照的である。
- 主な障壁には、薬物送達、腫瘍不均一性、微小環境、および免疫回避が含まれる。
- 新規薬剤、バイオマーカー、および併用療法が新たな機会として浮上している。
結論:
- フェロプトーシスは、腫瘍学における治療戦略として潜在性を持つ。
- 臨床応用のためには、トランスレーショナルバリアを克服することが不可欠である。
- フェロプトーシスに基づくがん治療の開発を加速するためには、戦略的なロードマップが必要である。
関連する概念動画
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Cancer Therapies
10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Translation
18.9K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
Translation Produces the Building Blocks of Life
Proteins are...
18.9K

